AB
SPRY icon

Amalgamated Bank’s ARS Pharmaceuticals SPRY Stock Holding History

Amalgamated Bank’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,853
Closed -$22K – 2657
2025
Q4 		$22K Buy
1,853
+171
+10% +$1.66K ﹤0.01% 2074
2025
Q3 		$17K Hold
1,682
– – ﹤0.01% 2212
2025
Q2 		$29K Hold
1,682
– – ﹤0.01% 1984
2025
Q1 		$21K Hold
1,682
– – ﹤0.01% 2048
2024
Q4 		$18K Hold
1,682
– – ﹤0.01% 2167
2024
Q3 		$24K Buy
1,682
+864
+106% +$10.3K ﹤0.01% 2064
2024
Q2 		$7K Hold
818
– – ﹤0.01% 2643
2024
Q1 		$8K Sell
818
-1,589
-66% -$11.8K ﹤0.01% 2543
2023
Q4 		$13K Sell
2,407
-243
-9% -$1.06K ﹤0.01% 2819
2023
Q3 		$10K Hold
2,650
– – ﹤0.01% 2898
2023
Q2 		$18K Buy
+2,650
New +$17.7K ﹤0.01% 2799
2022
Q2 		– Sell
-2,469
Closed -$9K – 3188
2022
Q1 		$9K Buy
+2,469
New +$10.7K ﹤0.01% 2979

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Amalgamated Bank's SPRY Position: Q1 2026 in Review

Amalgamated Bank sold out of ARS Pharmaceuticals (SPRY) in Q1 2026, closing a stake of 1,853 shares — an estimated $22K sold.

Amalgamated Bank first reported a position in SPRY in Q1 2022 and held it in 12 quarters. The position peaked at $29K in Q2 2025. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Amalgamated Bank reported no remaining ARS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,853 ARS Pharmaceuticals shares in Q1 2026, an estimated $22K.
  • Amalgamated Bank first reported a position in ARS Pharmaceuticals in Q1 2022 and held it in 12 quarters.
  • Amalgamated Bank's ARS Pharmaceuticals position peaked at $29K in Q2 2025.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.